Compare Kimberly Clark Corp (KMB) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs Natera Inc. Common Stock — how do they compare? Kimberly Clark Corp trades at $100.52 (market cap $32.69B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Kimberly Clark Corp pays a 5.21% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kimberly Clark Corp for 94 Days and Natera Inc. Common Stock for 0 Days on average.
| KMB | NTRA | |
|---|---|---|
Market Cap | $32.69B | $57.03B |
Volume | 6,331,515 | 1,131,157 |
Sector | Consumer Staples | Health |
52-Week High | $121.44 | $425.64 |
52-Week Low | $93.05 | $179.42 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $38.25B | $56.18B |
Dividend Yield | 5.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $99.41, up 0.65% on the day, showing modest recovery after recent declines. The stock faces technical headwinds with bearish moving averages and overbought RSI signals, while fundamentals reveal mixed results with Q2 2026 earnings miss but strong profitability margins. Recent executive transitions and the pending Kenvue acquisition dominate news flow, creating uncertainty around the company's strategic direction and cash flow sustainability.
KMB presents a complex investment case with a 5.16% dividend yield and 54-year dividend growth streak offset by acquisition risks and cash flow concerns. Analyst consensus at $117.25 suggests 18% upside potential, but the stock requires careful monitoring of integration execution and dividend coverage metrics amid changing leadership.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
